Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 6/20 | 0.63 |
| ▸ | PARP1 | P09874 | 5/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4369801 | 0.86 | TYMS (0.72) | TYMSPARP1TNKS2KDM4ENPC1 | |
| SCHEMBL30704851 | 0.82 | PARP1 (0.62) | TYMSPARP1TNKS2KDM4ENPC1 | |
| SCHEMBL17460813 | 0.82 | PARP1 (0.62) | TYMSPARP1TNKS2KDM4ENPC1 | |
| SCHEMBL6670119 | 0.79 | TYMS (0.63) | TYMSPARP1TNKS2KDM4ENPC1 | |
| SCHEMBL29440611 | 0.79 | TYMS (0.63) | TYMSPARP1TNKS2KDM4ENPC1 | |
| SCHEMBL38651189 | 0.79 | TYMS (0.47) | TYMSPARP1TNKS2KDM4EALDH1A1 | |
| SCHEMBL26017739 | 0.79 | PARP14 (0.49) | TYMSPARP1TNKS2KDM4EALDH1A1 | |
| SCHEMBL3226572 | 0.79 | TYMS (0.63) | TYMSPARP1TNKS2KDM4ENPC1 | |
| SCHEMBL578054 | 0.79 | PARP14 (0.46) | TYMSPARP1TNKS2KDM4EHPGD | |
| SCHEMBL17298079 | 0.79 | TNKS2 (0.62) | TYMSPARP1TNKS2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935246-B1 | ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3008053-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2009046536-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) | 2009-04-16 | — | — | WO | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080146562-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS INC., | 2008-06-19 | — | — | US | disclosed |
| US-20080146562-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS INC., | 2008-06-19 | — | — | US | disclosed |
| EP-1814552-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | Astex Therapeutics Limited (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006051290-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146562-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | HRH3, HRH1, NQO2 | TYMS 2570/4885PARP1 2980/4885TNKS2 3281/4885 |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | CNKSR1, PRKCH, PRKAR2B | TYMS 4517/4885PARP1 2645/4885TNKS2 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.